BME:NYE-BlackRock Health Sciences Trust (USD)

COMMON STOCK | Asset Management | NYE

Last Closing Price

USD 48.99

Change

+0.14 (+0.29)%

Market Cap

USD 0.56B

Volume

0.02M

Average Target Price

N/A
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

BlackRock Health Sciences Trust is a closed-ended equity mutual fund launched by BlackRock, Inc. The fund is managed by BlackRock Advisors, LLC. It invests in the public equity markets of the United States. The fund seeks to invest in stocks of companies operating in the health sciences and related sectors, which include businesses involved in researching, developing, producing, distributing or delivering medical, dental, optical, pharmaceutical or biotechnology products, supplies, equipment, or services. It also invests through equity derivatives, with an emphasis on option writing. The fund benchmarks the performance of its portfolio against the Russell 3000 Healthcare Index. BlackRock Health Sciences Trust was formed on March 31, 2005 and is domiciled in the United States.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-26 )

Largest Industry Peers for Asset Management

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
BLK BlackRock, Inc

-1.13 (-0.16%)

USD110.28B 22.70 16.51
BAM Brookfield Asset Management In..

+0.66 (+1.71%)

USD58.51B 42.28 14.06
BX The Blackstone Group Inc

-0.08 (-0.12%)

USD45.09B 57.61 N/A
BK-PC The Bank of New York Mellon Co..

N/A

USD41.70B 5.38 N/A
BK The Bank of New York Mellon Co..

+0.04 (+0.10%)

USD36.62B 10.78 N/A
STT State Street Corporation

+0.08 (+0.11%)

USD25.62B 11.48 N/A
AMP Ameriprise Financial, Inc

-0.34 (-0.16%)

USD24.97B 14.85 N/A
KKR KKR & Co. Inc

-0.40 (-1.01%)

USD22.51B 23.17 15.05
STT-PG State Street Corporation

-0.03 (-0.10%)

USD22.09B 4.55 N/A
STT-PD State Street Corporation

+0.05 (+0.18%)

USD21.78B 4.50 N/A

ETFs Containing BME

Symbol Name Weight Mer Price(Change) Market Cap
SCID Global X Scientific Beta .. 0.00 % 0.39 %

N/A

USD3.34M

Market Performance

  Market Performance vs.
Industry/Classification (Asset Management)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2.94% 72% C- 55% F
Dividend Return 0.42% 46% F 43% F
Total Return 3.36% 72% C- 58% F
Trailing 12 Months  
Capital Gain 16.50% 91% A- 71% C-
Dividend Return 5.71% 51% F 85% B
Total Return 22.21% 91% A- 75% C
Trailing 5 Years  
Capital Gain 40.49% 89% B+ 56% F
Dividend Return 33.84% 43% F 82% B-
Total Return 74.33% 82% B- 62% D-
Average Annual (5 Year Horizon)  
Capital Gain 5.31% 93% A 68% D+
Dividend Return 6.39% 55% F 90% A-
Total Return 11.69% 92% A- 78% C+
Risk Return Profile  
Volatility (Standard Deviation) 8.15% 69% D+ 78% C+
Risk Adjusted Return 143.54% 98% A+ 96% A
Market Capitalization 0.56B 74% C 43% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Asset Management)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 10.24 54% F 77% C+
Price/Book Ratio 1.16 12% F 64% D
Price / Cash Flow Ratio -39.89 96% A 95% A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity 12.59% 75% C 76% C
Return on Invested Capital 0.16% 11% F 25% F
Return on Assets 0.07% 5% F 22% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 1.37 13% F 61% D-
Short Percent 0.41% 30% F 90% A-
Beta 0.85 37% F 66% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.